Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 50, Topic 2
In Progress

Diagnosis and Risk Stratification of Acute Venous Thromboembolism

Lesson Progress
0% Complete
Diagnosis and Risk Stratification of Acute Venous Thromboembolism

Diagnosis and Risk Stratification of Acute Venous Thromboembolism

Objectives Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

Integrate clinical assessment, validated prediction tools, laboratory testing, and imaging to accurately diagnose VTE and stratify patient risk, guiding management decisions.

1. Clinical Assessment

Acute venous thromboembolism (VTE) encompasses a spectrum from deep vein thrombosis (DVT) to pulmonary embolism (PE). The initial evaluation hinges on recognizing specific symptom clusters, identifying risk factors, and performing a targeted physical examination to estimate the pretest probability of disease.

Symptom Clusters

  • Deep Vein Thrombosis (DVT): Typically presents with unilateral leg swelling, pain, tenderness along the deep venous system, pitting edema, and the appearance of collateral superficial veins.
  • Pulmonary Embolism (PE): Characterized by the sudden onset of dyspnea, pleuritic chest pain, tachypnea, tachycardia, and hypoxemia. Syncope may occur in cases of massive PE, signaling severe hemodynamic compromise.

Risk Factors & Physical Exam Triggers

A thorough history is crucial for identifying predisposing factors. Vital signs and a focused physical exam can reveal key triggers for suspecting VTE.

  • Major Risk Factors: Recent surgery (especially orthopedic), major trauma, prolonged immobilization, active cancer, and a personal history of VTE.
  • Minor Risk Factors: Obesity, pregnancy or the postpartum period, estrogen-containing therapy, and various chronic inflammatory or heart diseases.
  • Leg Exam: A difference in calf circumference greater than 3 cm between legs is a significant finding. Homan’s sign (calf pain on dorsiflexion) is neither sensitive nor specific and is not recommended.
  • Cardiopulmonary Exam: Look for jugular venous distension (JVD), a loud P2 heart sound, a right ventricular heave, new arrhythmias (like atrial fibrillation), or hemoptysis.
  • Vital Signs: Heart rate > 100 bpm, respiratory rate > 30 breaths/min, oxygen saturation (SpO₂) < 90%, or systolic blood pressure (SBP) < 90 mm Hg are all red flags.
Clinical Pearl Icon A lightbulb icon, representing a clinical tip or pearl. Clinical Pearl: VTE in Fluid Overload +

In patients with baseline bilateral edema from conditions like heart failure or cirrhosis, a sudden, superimposed unilateral increase in leg circumference is highly suspicious for DVT and should prompt an early ultrasound evaluation.

Clinical Pearl Icon A lightbulb icon, representing a clinical tip or pearl. Clinical Pearl: ECG Findings +

While classic ECG signs like S1Q3T3 pattern or new right-axis deviation can suggest right heart strain from a PE, they are present in a minority of cases and lack sufficient sensitivity to rule out the diagnosis.

2. Clinical Prediction Tools

Standardized scoring systems are essential for quantifying the pretest probability of VTE. These tools help standardize the diagnostic approach and identify patients who may be candidates for outpatient management.

Wells Score for DVT and PE

The Wells criteria are the most widely used tools to stratify patients into low, moderate, or high pretest probability groups.

Wells Score for DVT and PE
Clinical Feature Points (DVT) Points (PE)
Active cancer+1+1
Recent immobilization or surgery+1+1.5
Localized tenderness along deep veins+1
Entire leg swollen+1
Calf swelling ≥3 cm vs. other leg+1
Pitting edema (symptomatic leg)+1
Collateral superficial veins+1
Previous DVT/PE+1+1.5
Clinical signs/symptoms of DVT+3
Heart rate > 100 bpm+1.5
Hemoptysis+1
Alternative diagnosis less likely than PE+3
Alternative diagnosis at least as likely as DVT-2
Interpretation (DVT) ≤0: Low; 1–2: Moderate; ≥3: High
Interpretation (PE) ≤4: Low/Intermediate; >4: High

Prognostic Scores for PE: PESI and Hestia

Once PE is diagnosed, these scores help determine 30-day mortality risk and suitability for outpatient care.

  • Pulmonary Embolism Severity Index (PESI): A complex 11-variable score that classifies patients into five risk classes (I-V) with corresponding 30-day mortality risk.
  • Simplified PESI (sPESI): Assigns 1 point for each of: age >80, history of cancer, chronic cardiopulmonary disease, pulse ≥110, SBP <100, or SpO₂ <90%. A score of 0 indicates low risk (<1% mortality) and potential for outpatient management. A score of ≥1 indicates high risk.
  • Hestia Criteria: A set of exclusion criteria. If a patient meets any criterion (e.g., SBP <100, active bleeding, need for oxygen), they are generally considered ineligible for outpatient treatment.
Clinical Pearl Icon A lightbulb icon, representing a clinical tip or pearl. Clinical Pearl: Outpatient Management +

Patients with a new PE diagnosis who have an sPESI score of 0 and meet all Hestia criteria (all “no”) are excellent candidates for safe and effective outpatient management with a direct oral anticoagulant (DOAC), provided they have adequate social support and follow-up arranged.

3. Laboratory Evaluation

Laboratory tests, particularly D-dimer and cardiac biomarkers, play a crucial role in refining the diagnostic and risk stratification process.

D-dimer Assay

D-dimer is a fibrin degradation product. Its primary utility is to rule out VTE in patients with low or moderate pretest probability.

  • Performance: High sensitivity (>95%) but low specificity (<50%), meaning it is good at ruling out disease but poor at ruling it in.
  • Application: A negative D-dimer in a patient with a low/moderate Wells score effectively excludes VTE, avoiding the need for imaging. A positive result is non-specific and mandates imaging.
  • Age-Adjusted Cutoff: For patients over 50 years old, using a cutoff of (Patient’s Age × 10 µg/L) improves specificity without significantly compromising sensitivity, reducing unnecessary imaging in the elderly.

Cardiac Biomarkers

In patients with confirmed PE, cardiac biomarkers help stratify risk by indicating right ventricular (RV) strain.

Cardiac Biomarkers in PE Risk Stratification
Biomarker Typical Threshold Clinical Implication
Troponin I/T e.g., Troponin I >0.1 ng/mL Indicates myocardial micro-injury from acute RV pressure overload.
BNP / NT-proBNP e.g., BNP >90 pg/mL Reflects RV wall stretch and hemodynamic stress.
Note: Elevation of either biomarker in a hemodynamically stable patient classifies the PE as intermediate-risk (submassive).

4. Imaging Modalities

Definitive diagnosis of VTE requires imaging. The choice of modality depends on the suspected location (DVT vs. PE) and patient-specific factors.

Compression Ultrasound for DVT

Bedside or formal compression ultrasonography is the primary imaging test for suspected DVT.

  • Technique: The inability to compress a vein with the ultrasound probe is diagnostic of thrombosis. A two-point scan of the common femoral and popliteal veins is rapid and has a sensitivity >90% for proximal DVT.
  • Follow-up: If the initial scan is negative but clinical suspicion remains high (e.g., high Wells score), a serial scan in 5–7 days is recommended to detect any distal DVTs that may have extended proximally.

Computed Tomography Pulmonary Angiography (CTPA) for PE

CTPA is the gold standard for diagnosing PE, providing detailed anatomical information.

  • Findings: Directly visualizes intraluminal filling defects in the pulmonary arteries. It can also provide prognostic data by assessing RV size; an RV/LV diameter ratio >1.0 indicates RV strain.
  • Limitations: Requires intravenous contrast, posing a risk to patients with severe renal impairment (e.g., eGFR <30 mL/min/1.73 m²). It also involves radiation exposure (~3–5 mSv).
Clinical Pearl Icon A lightbulb icon, representing a clinical tip or pearl. Clinical Pearl: The RV/LV Ratio +

The RV/LV ratio measured on the axial view of a CTPA is a powerful prognostic marker. A ratio >1.0 is a key criterion for identifying intermediate-risk (submassive) PE and correlates with a worse short-term prognosis.

5. Classification of PE Severity

Stratifying PE severity based on hemodynamic stability, RV dysfunction, and biomarker status is critical for guiding treatment intensity, from standard anticoagulation to advanced therapies.

PE Severity Classification
Risk Category Hemodynamic Status RV Dysfunction Biomarker Elevation
Massive (High Risk) SBP <90 mmHg or Shock Usually Present Usually Present
Submassive (Intermediate-High Risk) SBP ≥90 mmHg Present Present
Submassive (Intermediate-Low Risk) SBP ≥90 mmHg Present OR Present (Only one is positive)
Low Risk SBP ≥90 mmHg Absent Absent

RV Dysfunction: Defined by signs on echocardiography (e.g., RV/LV ratio >1, TAPSE <16 mm) or CTPA (RV/LV ratio >1).
Biomarker Elevation: Positive troponin or elevated BNP/NT-proBNP.

Clinical Pearl Icon A lightbulb icon, representing a clinical tip or pearl. Clinical Pearl: The “Danger Zone” +

Submassive PE with both RV dysfunction and biomarker elevation (Intermediate-High Risk) represents a “danger zone.” These patients are hemodynamically stable but have a high risk of decompensation. They warrant admission to a higher level of care, such as a step-down unit or ICU, for close monitoring.

6. Decision Algorithms

Integrating clinical scores, lab tests, and imaging into structured pathways facilitates efficient and safe management, including determining the appropriate care setting and need for therapy escalation.

Diagnostic Algorithm for Suspected Pulmonary Embolism A flowchart showing the diagnostic pathway for suspected PE. It starts with assessing clinical probability using the Wells score. If probability is low or intermediate, D-dimer is checked. A negative D-dimer rules out PE. A positive D-dimer or high initial probability leads to CTPA. A positive CTPA confirms PE, while a negative one excludes it. Clinical Suspicion of PE Assess Pre-Test Probability (Wells Score) Measure D-dimer (Age-adjusted) Proceed to CT Pulmonary Angiogram CT Pulmonary Angiogram PE Excluded PE Confirmed PE Excluded Low/Intermediate High Negative Positive Negative Positive
Figure 1: Diagnostic Algorithm for Suspected PE. This pathway integrates pretest probability with targeted testing to efficiently diagnose or exclude PE.

Outpatient vs. Inpatient Pathways

  • Low-Risk PE: Patients with a confirmed PE but a sPESI score of 0 or who are Hestia-negative can often be managed as outpatients with a DOAC. This requires a reliable patient, adequate social support, and arranged follow-up within 48-72 hours.
  • Low-Risk DVT: Patients with a low Wells score (≤0) and a negative D-dimer do not require imaging. If the Wells score is ≥1 or the D-dimer is positive, an ultrasound is necessary. Most uncomplicated DVTs can be managed on an outpatient basis.

Escalation of Care

  • ICU Admission: Required for all patients with massive (high-risk) PE. Admission should also be strongly considered for patients with intermediate-high risk (submassive) PE, especially if there are signs of hemodynamic fragility.
  • Advanced Therapies: Systemic thrombolysis is the standard of care for massive PE without contraindications. In select submassive PE patients with worsening status, catheter-directed therapies may be considered.
Editor’s Note Icon A pencil icon, indicating an editor’s note or comment. Editor’s Note +

Insufficient detail on ICU protocols and advanced therapy selection. A complete section would include specific thrombolytic agents/doses, contraindications, and catheter-based techniques.

References

  1. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738.
  2. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545–e608.
  3. Yamashita Y, Morimoto T, Kimura T. Venous thromboembolism: Recent advancement and future perspective. J Cardiol. 2022;79(1):79–89.
  4. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603.
  5. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041–1046.
  6. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383–1389.
  7. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41–48.
  8. Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008;178(4):425–430.